https://thepharmadata.com/realta-life-sciences-appoints-lewis-t-williams-m-d-ph-d-as-chairman/ 2024-11-22T10:45:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/ReAlta-Life-Sciences-Appoints-Lewis-T.-Williams-M.D.-Ph.D.-as-Chairman_11zon-3_11zon.webp https://thepharmadata.com/population-health-research-institute-celebrates-25-years-of-advancing-global-health-research-and-innovation/ 2024-11-22T10:54:53+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Population-Health-Research-Institute-Celebrates-25-Years-of-Advancing-Global-Health-Research-and-Innovation-2_11zon.webp https://thepharmadata.com/versant-ventures-launches-pep2tango-therapeutics-inc/ 2024-11-22T10:59:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Versant-Ventures-Launches-Pep2Tango-Therapeutics-Inc_11zon.webp https://thepharmadata.com/fda-approves-attruby-acoramidis-to-reduce-cardiovascular-risks-in-attr-cm-patients/ 2024-11-25T09:37:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/FDA-Approves-Attruby™-acoramidis-to-Reduce-Cardiovascular-Risks-in-ATTR-CM-Patients.webp https://thepharmadata.com/can-cancer-be-treated-by-activating-the-bodys-defense-system/ 2024-11-25T09:58:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Can-Cancer-Be-Treated-by-Activating-the-Bodys-Defense-System_11zon.webp https://thepharmadata.com/halozyme-withdraws-acquisition-proposal-for-evotec-amid-lack-of-engagement/ 2024-11-25T10:18:05+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Halozyme-Withdraws-Acquisition-Proposal-for-Evotec-Amid-Lack-of-Engagement.webp https://thepharmadata.com/lebanon-a-conflict-devastating-health-care-systems/ 2024-11-25T10:24:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Lebanon-A-Conflict-Devastating-Health-Care-Systems_11zon.webp https://thepharmadata.com/global-leaders-unite-with-jeddah-commitments-to-combat-antimicrobial-resistance/ 2024-11-25T10:35:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Global-Leaders-Unite-with-Jeddah-Commitments-to-Combat-Antimicrobial-Resistance_11zon-scaled.webp https://thepharmadata.com/enanta-pharmaceuticals-announces-fiscal-q4-and-full-year-2024-financial-results/ 2024-11-26T12:34:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Enanta-Pharmaceuticals-Announces-Fiscal-Q4-and-Full-Year-2024-Financial-Results.webp https://thepharmadata.com/bicycle-therapeutics-to-present-zelenectide-pevedotin-data-at-sabcs-2024/ 2024-11-26T12:39:15+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Bicycle-Therapeutics-to-Present-Zelenectide-Pevedotin-Data-at-SABCS-2024.webp https://thepharmadata.com/exact-sciences-showcases-oncotype-dx-and-genomic-research-at-sabcs-2024/ 2024-11-26T12:43:46+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Exact-Sciences-Showcases-Oncotype-DX®-and-Genomic-Research-at-SABCS-2024.webp https://thepharmadata.com/menarini-showcases-orserdu-advances-at-sabcs-2024-for-er-her2-mbc/ 2024-11-26T12:48:29+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Menarini-Showcases-ORSERDU®-Advances-at-SABCS-2024-for-ER-HER2-mBC.webp https://thepharmadata.com/genentech-shares-latest-findings-from-phase-iii-skyscraper-01-study/ 2024-11-26T12:52:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Genentech-Shares-Latest-Findings-from-Phase-III-SKYSCRAPER-01-Study.webp https://thepharmadata.com/second-ihr-emergency-meeting-on-mpox-surge-2024/ 2024-11-29T09:46:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Second-IHR-Emergency-Meeting-on-Mpox-Surge-2024_11zon.webp https://thepharmadata.com/new-guidance-for-sustainable-climate-resilient-healthcare-facilities/ 2024-11-29T09:46:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/New-Guidance-for-Sustainable-Climate-Resilient-Healthcare-Facilities.webp https://thepharmadata.com/altasciences-partners-with-metsera-to-advance-early-stage-clinical-trials-for-obesity-treatment/ 2024-11-29T09:45:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Altasciences-Partners-with-Metsera-to-Advance-Early-Stage-Clinical-Trials-for-Obesity-Treatment_11zon.webp https://thepharmadata.com/global-head-and-neck-cancer-therapeutics-market-2024-overview-and-2030-forecast/ 2024-11-29T10:03:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Global-Head-and-Neck-Cancer-Therapeutics-Market.webp https://thepharmadata.com/dr-reddys-launches-toripalimab-in-india-first-immuno-oncology-drug-for-nasopharyngeal-carcinoma/ 2024-11-29T15:29:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Dr.-Reddys-Launches-Toripalimab-in-India-First-Immuno-Oncology-Drug-for-Nasopharyngeal-Carcinoma.webp https://thepharmadata.com/new-report-urges-continued-investment-in-infection-prevention-programs/ 2024-11-30T10:13:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/New-Report-Urges-Continued-Investment-in-Infection-Prevention-Programs_11zon.webp https://thepharmadata.com/eu-approves-beigenes-tevimbra-for-advanced-esophageal-and-gastric-cancer-treatment/ 2024-11-30T10:24:40+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/EU-Approves-BeiGenes-TEVIMBRA-for-Advanced-Esophageal-and-Gastric-Cancer-Treatment_11zon.webp https://thepharmadata.com/ucb-advances-new-launches-and-divests-mature-product-business-in-china/ 2024-11-30T10:42:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/UCB-Advances-New-Launches-and-Divests-Mature-Product-Business-in-China_11zon-1.webp https://thepharmadata.com/bayer-expands-global-incubator-network-with-co-lab-berlin-welcomes-myopax-as-first-resident/ 2024-11-30T10:52:29+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Bayer-Expands-Global-Incubator-Network-with-Co.Lab-Berlin-Welcomes-MyoPax-as-First-Resident_11zon.webp https://thepharmadata.com/generic-injectables-market-report-2024-2030-patent-expirations-and-new-opportunities/ 2024-11-30T11:12:01+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Generic-Injectables-Market-Report-2024-2030-Patent-Expirations-and-New-Opportunities_11zon.webp https://thepharmadata.com/devonian-reports-2024-annual-financial-results/ 2024-11-30T11:16:40+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Devonian-Reports-2024-Annual-Financial-Results_11zon.webp https://thepharmadata.com/laser-photonics-launches-rd-initiative-to-drive-innovation/ 2024-11-30T11:23:50+05:30 https://thepharmadata.com/wp-content/uploads/2024/11/Laser-Photonics-Launches-RD-Initiative-to-Drive-Innovation_11zon.webp https://thepharmadata.com/ge-healthcare-showcases-ai-driven-innovations-and-precision-care-solutions-at-rsna-2024/ 2024-12-02T09:54:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/GE-HealthCare-Showcases-AI-Driven-Innovations-and-Precision-Care-Solutions-at-RSNA-2024_11zon.webp https://thepharmadata.com/biopharma-tackles-deadly-brain-cancer-after-years-of-setbacks/ 2024-12-02T12:48:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Biopharma-Tackles-Deadly-Brain-Cancer-After-Years-of-Setbacks_11zon.webp https://thepharmadata.com/fda-accelerated-approval-boosts-hope-for-fatal-diseases/ 2024-12-02T12:57:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Accelerated-Approval-Boosts-Hope-for-Fatal-Diseases_11zon.webp https://thepharmadata.com/digital-twins-advancing-clinical-research-and-bridging-data-gaps/ 2024-12-02T13:03:31+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Digital-Twins-Advancing-Clinical-Research-and-Bridging-Data-Gaps_11zon.webp https://thepharmadata.com/ge-healthcare-to-fully-acquire-nihon-medi-physics-from-sumitomo-chemical/ 2024-12-02T14:20:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/GE-HealthCare-to-Fully-Acquire-Nihon-Medi-Physics-from-Sumitomo-Chemical_11zon.webp https://thepharmadata.com/chmp-backs-palforzia-for-treating-peanut-allergy-in-toddlers/ 2024-12-02T14:49:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/CHMP-Backs-Palforzia-for-Treating-Peanut-Allergy-in-Toddlers_11zon.webp https://thepharmadata.com/orions-nordic-pharmaceutical-manufacturing-ensures-security-across-europe/ 2024-12-03T09:41:50+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Orions-Nordic-Pharmaceutical-Manufacturing-Ensures-Security-Across-Europe_11zon.webp https://thepharmadata.com/revolution-medicines-shares-clinical-updates-on-rason-inhibitor-portfolio/ 2024-12-03T09:47:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Revolution-Medicines-Shares-Clinical-Updates-on-RASON-Inhibitor-Portfolio_11zon.webp https://thepharmadata.com/melinta-joins-nhias-future-of-infusion-advisory-council/ 2024-12-03T10:15:18+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Melinta-Joins-NHIAs-Future-of-Infusion-Advisory-Council_11zon.webp https://thepharmadata.com/new-biovanta-study-demonstrates-highest-efficacy-in-treating-common-cold/ 2024-12-03T10:45:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Daiichi-Sankyo-Showcases-Oncology-Progress-at-ESMO-Asia_-SABCS_-and-ASH.webp https://thepharmadata.com/daiichi-sankyo-showcases-oncology-progress-at-esmo-asia-sabcs-and-ash/ 2024-12-03T10:34:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Daiichi-Sankyo-Showcases-Oncology-Progress-at-ESMO-Asia-SABCS-and-ASH_11zon.webp https://thepharmadata.com/revolution-medicines-prices-750m-public-offering/ 2024-12-04T09:40:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Revolution-Medicines-Prices-750M-Public-Offering_11zon.webp https://thepharmadata.com/ono-and-congruence-partner-on-oncology-drug-discovery/ 2024-12-04T09:51:08+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Ono-and-Congruence-Partner-on-Oncology-Drug-Discovery.webp https://thepharmadata.com/report-from-the-40th-polio-ihr-emergency-committee-meeting/ 2024-12-04T09:57:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Report-from-the-40th-Polio-IHR-Emergency-Committee-Meeting_11zon.webp https://thepharmadata.com/intra-cellular-therapies-files-snda-for-caplyta-as-adjunctive-mdd-treatment/ 2024-12-04T15:57:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Intra-Cellular-Therapies-Files-sNDA-for-CAPLYTA®-as-Adjunctive-MDD-Treatment-1.webp https://thepharmadata.com/ipsen-biomunex-sign-global-deal-for-mait-cell-engager-in-immuno-oncology/ 2024-12-04T10:27:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Ipsen-Biomunex-Sign-Global-Deal-for-MAIT-Cell-Engager-in-Immuno-Oncology_11zon-1.webp https://thepharmadata.com/intra-cellular-seeks-depression-approval-for-caplyta-as-stock-remains-under-the-radar/ 2024-12-04T10:34:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Intra-Cellular-Seeks-Depression-Approval-for-Caplyta-as-Stock-Remains-Under-the-Radar_11zon.webp https://thepharmadata.com/roche-forms-partnership-with-cour-in-autoimmune-disease-deal-worth-over-900m/ 2024-12-04T10:38:06+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Roche-Forms-Partnership-with-COUR-in-Autoimmune-Disease-Deal-Worth-Over-900M_11zon.webp https://thepharmadata.com/fda-grants-breakthrough-therapy-designation-to-sacituzumab-tirumotecan-for-egfr-nsclc/ 2024-12-04T10:46:01+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Grants-Breakthrough-Therapy-Designation-to-Sacituzumab-Tirumotecan-for-EGFR-NSCLC_11zon.webp https://thepharmadata.com/cvs-health-appoints-new-leaders-in-pharmacy-and-consumer-wellness-divisions/ 2024-12-04T10:54:19+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/CVS-Health-Appoints-New-Leaders-in-Pharmacy-and-Consumer-Wellness-Divisions_11zon.webp https://thepharmadata.com/novo-nordisk-to-present-new-data-on-sickle-cell-disease-and-hemophilia-at-ash-2024/ 2024-12-04T10:59:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Novo-Nordisk-to-Present-New-Data-on-Sickle-Cell-Disease-and-Hemophilia-at-ASH-2024_11zon.webp https://thepharmadata.com/teva-reports-positive-phase-3-results-for-ajovy-in-preventing-migraines-in-youth/ 2024-12-05T09:23:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Teva-Reports-Positive-Phase-3-Results-for-AJOVY-in-Preventing-Migraines-in-Youth_11zon.webp https://thepharmadata.com/who-approves-first-prequalified-tuberculosis-diagnostic-test/ 2024-12-05T09:35:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/WHO-Approves-First-Prequalified-Tuberculosis-Diagnostic-Test_11zon.webp https://thepharmadata.com/tips-for-staying-healthy-during-the-holidays/ 2024-12-05T09:51:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Tips-for-Staying-Healthy-During-the-Holidays_11zon.webp https://thepharmadata.com/beigene-and-cll-society-partner-to-promote-biomarker-testing-in-cll/ 2024-12-05T09:56:13+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/BeiGene-and-CLL-Society-Partner-to-Promote-Biomarker-Testing-in-CLL_11zon.webp https://thepharmadata.com/fda-issues-warning-to-applied-therapeutics-over-objectionable-conditions-in-govorestat-study/ 2024-12-05T10:03:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Issues-Warning-to-Applied-Therapeutics-Over-Objectionable-Conditions-in-Govorestat-Study_11zon.webp https://thepharmadata.com/lilly-clinches-major-weight-loss-win-over-novo-in-head-to-head-study/ 2024-12-05T10:16:58+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lilly-Clinches-Major-Weight-Loss-Win-Over-Novo-in-Head-to-Head-Study.webp https://thepharmadata.com/who-prequalifies-first-single-dose-medicine-for-p-vivax-malaria-and-includes-it-in-guidelines/ 2024-12-05T10:24:08+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/WHO-Prequalifies-First-Single-Dose-Medicine-for-P.-vivax-Malaria-and-Includes-it-in-Guidelines._11zon.webp https://thepharmadata.com/astrazeneca-appoints-iskra-reic-as-evp-international/ 2024-12-05T10:31:52+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/AstraZeneca-Appoints-Iskra-Reic-as-EVP-International_11zon.webp https://thepharmadata.com/cvs-health-corporation-announces-pricing-for-comprehensive-tender-offer/ 2024-12-07T10:01:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/CVS-Health-Corporation-Announces-Pricing-for-Comprehensive-Tender-Offer_11zon.webp https://thepharmadata.com/eu-approves-novo-holdings-catalent-acquisition-and-novo-nordisks-site-purchase/ 2024-12-07T10:10:58+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/EU-Approves-Novo-Holdings-Catalent-Acquisition-and-Novo-Nordisks-Site-Purchase_11zon.webp https://thepharmadata.com/leqembi-lecanemab-gains-approval-in-mexico-for-early-alzheimers-treatment/ 2024-12-07T10:33:58+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/LEQEMBI-Lecanemab-Gains-Approval-in-Mexico-for-Early-Alzheimers-Treatment.webp https://thepharmadata.com/webinar-leveraging-digital-and-analytics-tools-in-mpox-response/ 2024-12-07T11:00:46+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Webinar-Leveraging-Digital-and-Analytics-Tools-in-Mpox-Response_11zon.webp https://thepharmadata.com/senegal-and-rwanda-attain-who-maturity-level-3-for-medicines-regulation/ 2024-12-07T11:11:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Senegal-and-Rwanda-Attain-WHO-Maturity-Level-3-for-Medicines-Regulation_11zon.webp https://thepharmadata.com/imfinzi-receives-priority-review-in-us-for-muscle-invasive-bladder-cancer/ 2024-12-07T11:31:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/IMFINZI-Receives-Priority-Review-in-US-for-Muscle-Invasive-Bladder-Cancer-2_11zon.webp https://thepharmadata.com/childrens-hospital-los-angeles-marks-100th-retinal-gene-therapy-procedure/ 2024-12-07T11:42:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Childrens-Hospital-Los-Angeles-Marks-100th-Retinal-Gene-Therapy-Procedure.webp https://thepharmadata.com/alithea-genomics-unveils-full-length-drug-seq-to-enhance-transcriptomics-in-drug-discovery/ 2024-12-07T11:46:26+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Alithea-Genomics-Unveils-Full-Length-DRUG-Seq-to-Enhance-Transcriptomics-in-Drug-Discovery_11zon.webp https://thepharmadata.com/stoke-therapeutics-presents-data-supporting-zorevunersen-as-treatment-for-dravet-syndrome/ 2024-12-09T09:09:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Stoke-Therapeutics-Presents-Data-Supporting-Zorevunersen-as-Treatment-for-Dravet-Syndrome_11zon.webp https://thepharmadata.com/an-innovative-approach-to-efficient-anti-cancer-drug-synthesis/ 2024-12-09T09:53:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/An-Innovative-Approach-to-Efficient-Anti-Cancer-Drug-Synthesis_11zon-1.webp https://thepharmadata.com/abbvie-releases-report-on-mental-health-in-underrepresented-cll-patients/ 2024-12-09T09:56:41+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/AbbVie-Releases-Report-on-Mental-Health-in-Underrepresented-CLL-Patients_11zon.webp https://thepharmadata.com/blueprint-medicines-showcases-leadership-in-systemic-mastocytosis-at-2024-ash-meeting/ 2024-12-09T10:03:50+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Blueprint-Medicines-Showcases-Leadership-in-Systemic-Mastocytosis-at-2024-ASH-Meeting_11zon.webp https://thepharmadata.com/incyte-reports-positive-phase-3-results-for-retifanlimab-in-nsclc/ 2024-12-09T10:15:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Incyte-Reports-Positive-Phase-3-Results-for-Retifanlimab-in-NSCLC_11zon.webp https://thepharmadata.com/epcoritamab-monotherapy-shows-high-response-rates-in-r-r-cll-trial/ 2024-12-09T10:26:08+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Epcoritamab-Monotherapy-Shows-High-Response-Rates-in-RR-CLL-Trial_11zon.webp https://thepharmadata.com/epcoritamab-combination-therapy-shows-high-response-rates-in-r-r-follicular-lymphoma-trial/ 2024-12-09T10:32:27+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Epcoritamab-Combination-Therapy-Shows-High-Response-Rates-in-RR-Follicular-Lymphoma-Trial_11zon.webp https://thepharmadata.com/kite-presents-new-data-on-yescarta-in-relapsed-refractory-large-b-cell-lymphoma-at-ash/ 2024-12-09T10:40:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Kite-Presents-New-Data-on-Yescarta-in-RelapsedRefractory-Large-B-cell-Lymphoma-at-ASH_11zon.webp https://thepharmadata.com/pozelimab-cemdisiran-combo-surpasses-ravulizumab-in-controlling-pnh-hemolysis/ 2024-12-09T10:57:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Pozelimab-Cemdisiran-Combo-Surpasses-Ravulizumab-in-Controlling-PNH-Hemolysis_11zon-2_11zon.webp https://thepharmadata.com/epcoritamab-shows-durable-responses-in-large-b-cell-lymphoma-trials/ 2024-12-10T10:33:24+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Epcoritamab-Shows-Durable-Responses-in-Large-B-Cell-Lymphoma-Trials_11zon.webp https://thepharmadata.com/carvykti-boosts-mrd-negativity-in-relapsed-multiple-myeloma/ 2024-12-10T10:57:05+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/CARVYKTI-Boosts-MRD-Negativity-in-Relapsed-Multiple-Myeloma_11zon.webp https://thepharmadata.com/biogen-names-tim-power-as-head-of-investor-relations/ 2024-12-10T11:16:39+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Biogen-Names-Tim-Power-as-Head-of-Investor-Relations_11zon.webp https://thepharmadata.com/silal-and-bayer-strengthen-agricultural-partnership-with-mou/ 2024-12-11T09:55:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/SILAL-and-Bayer-Strengthen-Agricultural-Partnership-with-MOU_11zon.webp https://thepharmadata.com/roche-highlights-columvi-lunsumio-data-at-ash-2024-for-lymphoma-treatment/ 2024-12-11T09:52:10+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Roche-Highlights-Columvi-Lunsumio-Data-at-ASH-2024-for-Lymphoma-Treatment-2_11zon.webp https://thepharmadata.com/bio-techne-unveils-esr1-mutation-monitoring-assay/ 2024-12-11T10:09:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Bio-Techne-Unveils-ESR1-Mutation-Monitoring-Assay_11zon.webp https://thepharmadata.com/friends-of-traditional-medicine-set-2025-action-agenda/ 2024-12-11T10:22:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Friends-of-Traditional-Medicine-Set-2025-Action-Agenda_11zon.webp https://thepharmadata.com/agilents-pd-l1-ihc-28-8-pharmdx-companion-diagnostic-assay-earns-european-ivdr-certification/ 2024-12-11T10:43:35+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Agilents-PD-L1-IHC-28-8-pharmDx-Companion-Diagnostic-Assay-Earns-European-IVDR-Certification_11zon.webp https://thepharmadata.com/city-of-hope-experts-showcase-innovative-cancer-therapies-at-ash-annual-conference/ 2024-12-11T10:51:15+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/City-of-Hope-Experts-Showcase-Innovative-Cancer-Therapies-at-ASH-Annual-Conference_11zon.webp https://thepharmadata.com/crown-bioscience-receives-2024-fierce-cro-award-for-outstanding-client-service-and-partnership/ 2024-12-12T09:29:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Crown-Bioscience-Receives-2024-Fierce-CRO-Award-for-Outstanding-Client-Service-and-Partnership_11zon.webp https://thepharmadata.com/sk-pharmteco-combines-leading-brands-to-establish-a-global-cdmo-powerhouse/ 2024-12-12T09:35:33+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/SK-Pharmteco-Combines-Leading-Brands-to-Establish-a-Global-CDMO-Powerhouse_11zon.webp https://thepharmadata.com/health-canada-approves-celltrions-omlyclo-ct-p39-canadas-first-omalizumab-biosimilar/ 2024-12-12T09:43:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Health-Canada-Approves-Celltrions-Omlyclo-CT-P39-Canadas-First-Omalizumab-Biosimilar.webp https://thepharmadata.com/sirius-therapeutics-reports-promising-phase-i-data-for-next-gen-anticoagulant/ 2024-12-12T09:49:57+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Sirius-Therapeutics-Reports-Promising-Phase-I-Data-for-Next-Gen-Anticoagulant_11zon.webp https://thepharmadata.com/menarini-and-medsir-present-phase-iii-adela-study-new-strategy-for-advanced-breast-cancer/ 2024-12-12T10:00:12+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Menarini-and-MEDSIR-Present-Phase-III-ADELA-Study-New-Strategy-for-Advanced-Breast-Cancer_11zon.webp https://thepharmadata.com/antisense-rnai-therapeutics-market-2024-key-players-overview/ 2024-12-12T10:13:49+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Antisense-RNAi-Therapeutics-Market-2024-Key-Players-Overview_11zon.webp https://thepharmadata.com/sonarmd-data-reveals-anxiety-increases-risks-of-ibd-flares-and-severity/ 2024-12-12T10:18:00+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/SonarMD-Data-Reveals-Anxiety-Increases-Risks-of-IBD-Flares-and-Severity_11zon.webp https://thepharmadata.com/cyrus-biotechnology-announces-redosability-of-ides-protease-for-igg-driven-autoimmune-disease/ 2024-12-12T10:26:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Cyrus-Biotechnology-Announces-Redosability-of-IdeS-Protease-for-IgG-driven-Autoimmune-Disease_11zon.webp https://thepharmadata.com/pfizers-ibrance-extends-progression-free-survival-in-hr-her2-breast-cancer/ 2024-12-14T10:36:39+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Pfizers-IBRANCE-Extends-Progression-Free-Survival-in-HR-HER2-Breast-Cancer.webp https://thepharmadata.com/lynparza-shows-survival-benefit-in-early-breast-cancer-olympia-trial/ 2024-12-14T10:48:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lynparza-Shows-Survival-Benefit-in-Early-Breast-Cancer-OlympiA-Trial_11zon.webp https://thepharmadata.com/mercks-welireg-gains-eu-chmp-backing-for-vhl-tumors-and-advanced-rcc/ 2024-12-14T10:56:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Mercks-WELIREG-Gains-EU-CHMP-Backing-for-VHL-Tumors-and-Advanced-RCC_11zon.webp https://thepharmadata.com/abbvie-to-acquire-nimble-therapeutics-further-strengthening-immunology-pipeline/ 2024-12-14T11:03:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/AbbVie-to-Acquire-Nimble-Therapeutics-Further-Strengthening-Immunology-Pipeline_11zon.webp https://thepharmadata.com/lillys-omvoh-receives-chmp-recommendation-for-crohns-disease-approval/ 2024-12-14T11:17:41+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lillys-Omvoh-Receives-CHMP-Recommendation-for-Crohns-Disease-Approval_11zon.webp https://thepharmadata.com/fda-grants-breakthrough-therapy-designation-to-tolebrutinib-for-non-relapsing-secondary-progressive-ms/ 2024-12-14T11:29:41+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Grants-Breakthrough-Therapy-Designation-to-Tolebrutinib-for-Non-Relapsing-Secondary-Progressive-MS_11zon.webp https://thepharmadata.com/takeda-highlights-late-stage-pipeline-advancing-transformative-treatments-across-multiple-areas/ 2024-12-14T11:38:43+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Takeda-Highlights-Late-Stage-Pipeline-Advancing-Transformative-Treatments-Across-Multiple-Areas_11zon.webp https://thepharmadata.com/acoramidis-granted-positive-chmp-opinion-for-transthyretin-amyloid-cardiomyopathy-treatment/ 2024-12-14T11:41:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Acoramidis-Granted-Positive-CHMP-Opinion-for-Transthyretin-Amyloid-Cardiomyopathy-Treatment_11zon.webp https://thepharmadata.com/neurocrine-announces-fda-approval-of-crenessity-for-congenital-adrenal-hyperplasia/ 2024-12-14T11:56:46+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Neurocrine-Announces-FDA-Approval-of-CRENESSITY-for-Congenital-Adrenal-Hyperplasia_11zon.webp https://thepharmadata.com/lupin-acquires-3-diabetes-trademarks-from-boehringer-ingelheim/ 2024-12-14T11:59:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lupin-Acquires-3-Diabetes-Trademarks-from-Boehringer-Ingelheim_11zon.webp https://thepharmadata.com/lupin-digital-health-collaborates-with-medicover-hospitals-to-enhance-post-discharge-cardiac-care/ 2024-12-17T09:24:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lupin-Digital-Health-Collaborates-with-Medicover-Hospitals-to-Enhance-Post-Discharge-Cardiac-Care.webp https://thepharmadata.com/enhancing-health-and-care-worker-training-to-foster-resilient-health-systems/ 2024-12-17T09:36:12+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Enhancing-Health-and-Care-Worker-Training-to-Foster-Resilient-Health-Systems.webp https://thepharmadata.com/jazz-pharmaceuticals-unveils-ceo-succession-plan/ 2024-12-17T10:06:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Jazz-Pharmaceuticals-Unveils-CEO-Succession-Plan.webp https://thepharmadata.com/orchestra-study-insights-guide-next-steps-in-ucb-s-parkinsons-research-program/ 2024-12-17T10:17:43+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/ORCHESTRA-Study-Insights-Guide-Next-Steps-in-UCB-s-Parkinsons-Research-Program.webp https://thepharmadata.com/grifols-named-top-biotech-company-in-dow-jones-sustainability-indices/ 2024-12-17T10:22:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Grifols-Named-Top-Biotech-Company-in-Dow-Jones-Sustainability-Indices_11zon.webp https://thepharmadata.com/viiv-chmp-backs-long-acting-hiv-treatment-for-adolescents-in-europe/ 2024-12-17T10:34:52+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/ViiV-CHMP-Backs-Long-Acting-HIV-Treatment-for-Adolescents-in-Europe_11zon.webp https://thepharmadata.com/merck-updates-keyvibe-keyform-trials-for-cancer-combos/ 2024-12-17T10:39:58+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Merck-Updates-KeyVibe-KEYFORM-Trials-for-Cancer-Combos_11zon.webp https://thepharmadata.com/gilead-terray-partner-on-multi-target-small-molecule-therapies/ 2024-12-18T09:26:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Gilead-Terray-Partner-on-Multi-Target-Small-Molecule-Therapies_11zon.webp https://thepharmadata.com/fda-grants-breakthrough-status-to-trodelvy-for-2nd-line-es-sclc-treatment/ 2024-12-18T09:32:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Grants-Breakthrough-Status-to-Trodelvy-for-2nd-Line-ES-SCLC-Treatment_11zon.webp https://thepharmadata.com/duvakitug-phase-2b-results-highlight-potential-in-ibd-treatment/ 2024-12-18T09:38:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Duvakitug-Phase-2b-Results-Highlight-Potential-in-IBD-Treatment_11zon.webp https://thepharmadata.com/merck-announces-fda-bla-acceptance-for-clesrovimab-to-protect-infants-from-rsv/ 2024-12-18T09:48:42+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Merck-Announces-FDA-BLA-Acceptance-for-Clesrovimab-to-Protect-Infants-from-RSV_11zon.webp https://thepharmadata.com/lillys-kisunla-donanemab-azbt-approved-in-china-for-early-alzheimers-treatment/ 2024-12-18T09:53:01+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lillys-Kisunla-donanemab-azbt-Approved-in-China-for-Early-Alzheimers-Treatment_11zon.webp https://thepharmadata.com/lilly-and-eva-pharma-announce-regulatory-approval-and-launch-of-locally-manufactured-insulin-in-egypt/ 2024-12-18T09:58:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Lilly-and-EVA-Pharma-Announce-Regulatory-Approval-and-Launch-of-Locally-Manufactured-Insulin-in-Egypt_11zon.webp https://thepharmadata.com/eylea-hd-8-mg-phase-3-trial-shows-improved-vision-with-extended-dosing-in-macular-edema/ 2024-12-18T10:04:39+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/EYLEA-HD-8-mg-Phase-3-Trial-Shows-Improved-Vision-with-Extended-in-Macular-Edema_11zon.webp https://thepharmadata.com/aflibercept-8-mg-phase-iii-study-shows-vision-gains-with-extended-treatment-intervals-in-retinal-vein-occlusion/ 2024-12-18T10:15:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Aflibercept-8-mg-Phase-III-Study-Shows-Vision-Gains-with-Extended-Treatment-Intervals-in-Retinal-Vein-Occlusion_11zon.webp https://thepharmadata.com/teva-and-sanofi-announce-positive-phase-2b-results-for-duvakitug-in-ulcerative-colitis-and-crohns-disease/ 2024-12-18T10:24:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Teva-and-Sanofi-Announce-Positive-Phase-2b-Results-for-Duvakitug-in-Ulcerative-Colitis-and-Crohns-Disease_11zon.webp https://thepharmadata.com/viatris-publishes-phase-2b-care-study-data-on-cenerimod-in-lancet-rheumatology/ 2024-12-19T09:48:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Viatris-Publishes-Phase-2b-CARE-Study-Data-on-Cenerimod-in-Lancet-Rheumatology.jpg https://thepharmadata.com/hansoh-licenses-glp-1-agonist-hs-10535-to-msd-globally/ 2024-12-19T09:55:29+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Hansoh-Licenses-GLP-1-Agonist-HS-10535-to-MSD-Globally_11zon.webp https://thepharmadata.com/who-leaders-launch-who-academy-in-lyon/ 2024-12-19T17:39:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Macron-and-WHO-Leaders-Launch-WHO-Academy-in-Lyon_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/WHO-Academy-Launched-by-Marcron-And-World-Health-Organization-Leaders-1024x683.webp https://thepharmadata.com/merck-reports-phase-3-results-for-dor-isl-hiv-treatment/ 2024-12-20T10:05:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Merck-Reports-Phase-3-Results-for-DORISL-HIV-Treatment_11zon.webp https://thepharmadata.com/roche-prasinezumab-shows-potential-in-early-parkinsons-despite-phase-iib-miss/ 2024-12-20T10:14:43+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Roche-Prasinezumab-Shows-Potential-in-Early-Parkinsons-Despite-Phase-IIb-Miss_11zon.webp https://thepharmadata.com/merck-invests-e120m-in-shizuoka-advanced-materials-center/ 2024-12-20T10:17:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Merck-Invests-E120M-in-Shizuoka-Advanced-Materials-Center.webp https://thepharmadata.com/regeneron-advances-factor-xi-antibodies-to-phase-3-after-positive-phase-2-results/ 2024-12-20T10:23:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Regeneron-Advances-Factor-XI-Antibodies-to-Phase-3-After-Positive-Phase-2-Results_11zon.webp https://thepharmadata.com/aetna-launches-spanish-support-for-health-app-to-serve-diverse-communities/ 2024-12-20T10:38:45+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Aetna-Launches-Spanish-Support-for-Health-App-to-Serve-Diverse-Communities_11zon.webp https://thepharmadata.com/lilly-applauds-itc-ruling-on-counterfeit/ 2024-12-28T10:31:26+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/LillyApplauds-ITC-Ruling-on-Counterfeit-Tirzepatide-Imports_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/Lilly-Applauds-ITC-Ruling-on-Counterfeit-Tirzepatide-Imports_11zon-1024x576.webp https://thepharmadata.com/fda-approves-opdivo-qvantig-injection/ 2024-12-28T11:24:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Approves-Opdivo-Qvantig-Injection-for-Subcutaneous-Use-in-Adult-Solid-Tumor-Indications_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/FDA-Approves-Opdivo-Qvantig-Injection-for-Subcutaneous-Use-in-Adult-Solid-Tumor-Indications-2_11zon-1024x682.webp https://thepharmadata.com/positive-phase-3-results-for-psoriatic-arthritis/ 2024-12-28T11:52:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Bristol-Myers-Squibb-Announces-Positive-Phase-3-Results-for-Sotyktu-in-Psoriatic-Arthritis_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/Bristol-Myers-Squibb-Announces-Positive-Phase-3-Results-for-Sotyktu-in-Psoriatic-Arthritis-2_11zon-1024x682.webp https://thepharmadata.com/colorectal-cancer-breakthrough-bristol-myers/ 2024-12-28T12:56:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Bristol-Myers-Squibb-Gets-EC-Approval-for-Opdivo-Yervoy-in-MSI-High-Metastatic-Colorectal-Cancer_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/Bristol-Myers-Squibb-Gets-EC-Approval-for-Opdivo-Yervoy-in-MSI-High-Metastatic-Colorectal-Cancer-2_11zon-1024x682.webp https://thepharmadata.com/argenx-announces-vyvdura-cidp-in-adults/ 2024-12-30T10:27:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Argenx-Announces-VYVDURA-Approval-in-Japan-for-CIDP-in-Adults_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/Argenx-Announces-VYVDURA-Approval-in-Japan-for-CIDP-in-Adults_11zon-1-1024x682.webp https://thepharmadata.com/10-clinical-research-excellence-icon/ 2024-12-30T12:35:56+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/ICON-and-Employees-Recognized-for-Excellence-in-Clinical-Research_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/Clinical-Research-1024x683.webp https://thepharmadata.com/chemotherapy-tevimbra-approved-in-u-s-for-1st/ 2025-01-02T16:27:45+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/TEVIMBRA-Approved-in-U.S.-for-First-line-Treatment-of-Gastric-Cancers-with-Chemotherapy_11zon-1-scaled.webp https://thepharmadata.com/wp-content/uploads/2024/12/TEVIMBRA-Approved-in-U.S.-for-First-line-Treatment-of-Gastric-Cancers-with-Chemotherapy-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/12/TEVIMBRA-Approved-in-U.S.-for-First-line-Treatment-of-Gastric-Cancers-with-Chemotherapy-2_11zon_11zon-1-1024x555.webp https://thepharmadata.com/wuxi-biologics-and-sino-biopharm-forge-ground/ 2024-12-30T14:10:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/WuXi-Biologics-Sino-Biopharm-Ink-Deal-for-Biologics-Discovery_11zon-1.webp https://thepharmadata.com/wp-content/uploads/2024/12/WuXi-Biologics-Sino-Biopharm-Ink-Deal-for-Biologics-Discovery-2_11zon-1024x682.webp https://thepharmadata.com/kamal-adwan-hospital-shut-down-after-raid/ 2024-12-31T12:02:15+05:30 https://thepharmadata.com/wp-content/uploads/2024/12/Kamal-Adwan-Hospital-Shut-Down-After-Raid-and-Repeated-Attacks_11zon-scaled.webp https://thepharmadata.com/wp-content/uploads/2024/12/Kamal-Adwan-Hospital-Shut-Down-After-Raid-and-Repeated-Attacks-2_11zon-1024x682.webp https://thepharmadata.com/cancer-immunotherapy-market-2025-2029-insights/ 2025-01-02T14:04:20+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Cancer-Immunotherapy-Market-2025-2029-Insights-Forecasts_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Cancer-Immunotherapy-Market-2025-2029-Insights-Forecasts_11zon-1.webp https://thepharmadata.com/wp-content/uploads/2025/01/Immunotherapy_11zon.webp https://thepharmadata.com/os-therapies-completes-6-million-private-place/ 2025-01-02T14:38:44+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/OS-Therapies-Completes-6-Million-Private-Placement_11zon-scaled.webp https://thepharmadata.com/wp-content/uploads/2025/01/A-Breakthrough-in-Pediatric-Cancer-Treatment-OST-HER2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/OS-Therapies-Completes-6-Million-Private-Placement-2_11zon.webp https://thepharmadata.com/growth-in-precision-medicine-fabric-genomics-4/ 2025-01-02T15:53:01+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Precision-Medicine-Software-Market-2024-Key-Players-Syapse-Fabric-Genomics-Foundation-Medicine-Intel_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Precision-Medicine-Software-Market-2024-Key-Players-Syapse-Fabric-Genomics-Foundation-Medicine-Intel-2_11zon-1024x682.webp https://thepharmadata.com/wp-content/uploads/2025/01/Precision-Medicine-Software-Market-2024-Key-Players-Syapse-Fabric-Genomics-Foundation-Medicine-Intel-3_11zon-1024x682.webp https://thepharmadata.com/wp-content/uploads/2025/01/Genomics-Growth-in-Precision-Medicine-Software-Market-2024-4-Key-Players-Syapse-Fabric-Genomics-Foundation-Medicine-Intel_11zon-1024x682.webp https://thepharmadata.com/biologics-leader-wuxi-tops-2024-dow-jones/ 2025-01-03T10:32:04+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WuXi-Biologics-Tops-2024-Dow-Jones-Sustainability-Indices-for-the-Second-Year-in-a-Row_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Biologics-WuXi-Biologics-Tops-2024-Dow-Jones-Sustainability-Indices-for-the-Second-Year-in-a-Row_11zon-1024x682.webp https://thepharmadata.com/propranolol-alleviates-tremors-in-parkinsons/ 2025-01-03T11:36:34+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Propranolol-Alleviates-Tremors-in-Parkinsons-Disease_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Propranolol-Alleviates-Tremors-in-Parkinsons-Disease-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Implications-for-Treatment-and-Future-Research_11zon.webp https://thepharmadata.com/drug-approvals-cancer-incidence-drive-400/ 2025-01-03T12:32:27+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/400-Bn-Oncology-Market-by-2029-Cancer-Incidence-Drug-Approvals-Drive-Growth.webp https://thepharmadata.com/wp-content/uploads/2025/01/Drug-Approvals-Cancer-Incidence-Drive-400-Bn-Oncology-Market-by-2029_11zon-1024x535.webp https://thepharmadata.com/pharmaessentia-commits-to-reliable-access-to/ 2025-01-03T12:50:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/PharmaEssentia-Commits-to-Reliable-Access-to-Interferon-Therapies-Amid-Supply-Challenges_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/PharmaEssentia-Commits-to-Reliable-Access-to-Interferon-Therapies-Amid-Supply-Challenges-2_11zon.webp https://thepharmadata.com/cytokinetics-announces-inducement-grants-in/ 2025-01-04T10:56:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Cytokinetics-Announces-Inducement-Grants-in-Compliance-with-Nasdaq-Rule-5635C4_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Cytokinetics-Announces-Inducement-Grants-in-Compliance-with-Nasdaq-Rule-5635C5_11zon-1.webp https://thepharmadata.com/pearland-event-highlights-heart-disease-risks/ 2025-01-04T11:58:15+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Pearland-Event-Highlights-Heart-Disease-Risks-with-Free-Heart-and-Kidney-Health-Screenings_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Heart-Disease-Pearland-Event-Highlights-Risks-with-Free-Heart-and-Kidney-Health-Screenings_11zon.webp https://thepharmadata.com/revolution-medicines-closes-landmark-upsized/ 2025-01-06T11:09:56+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Revolution-Medicines-Closes-Upsized-Offering-and-Underwriters-Option_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Revolution-Medicines-Closes-Upsized-Offering-and-Underwriters-Option-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Biopharmaceutical-Industry_11zon-1024x683.webp https://thepharmadata.com/nmpa-approves-vyloytm-advanced-gastric-cancer/ 2025-01-06T11:40:22+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/NMPA-Approves-VYLOYTM-for-Advanced-Gastric-Cancer-Treatment.webp https://thepharmadata.com/wp-content/uploads/2025/01/Clinical-Trial-Results_11zon-1.webp https://thepharmadata.com/wp-content/uploads/2025/01/NMPA-Approves-VYLOYTM-for-Advanced-Gastric-Cancer-Treatment_11zon-1.webp https://thepharmadata.com/biopharma-leaders-head-to-jpmorgan-in-search/ 2025-01-06T12:00:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Biopharma-Leaders-Head-to-JPMorgan-in-Search-of-MA-Boost-to-Revive-Market-Sentiment_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Biopharma-Leaders-Head-to-JPMorgan-in-Search-of-MA-Boost-to-Revive-Market-Sentiment-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Biopharma_11zon-1.webp https://thepharmadata.com/hiv-testing-who-unveils-new-guidelines-for/ 2025-01-07T09:56:18+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WHO-Unveils-New-Guidelines-for-Lenacapavir-and-Updated-HIV-Testing-Recommendations_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/HIV-Testing-WHO-Unveils-New-Guidelines-for-Lenacapavir-and-Updated-Recommendations_11zon-1024x576.webp https://thepharmadata.com/trispecific-wuxi-biologics-partners-with-2024/ 2025-01-07T10:30:24+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WuXi-Biologics-Partners-with-Candid-Therapeutics-on-Trispecific-T-Cell-Engager-Agreement_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Trispecific-WuXi-Biologics-Partners-with-Candid-Therapeutics-on-T-Cell-Engager-Agreement_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Impact-on-the-Biopharmaceutical-Landscape_11zon-1024x576.webp https://thepharmadata.com/hub-organoids-acq-by-500-million/ 2025-01-07T11:07:20+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Merck-Acquires-HUB-Organoids-to-Expand-Biology-Portfolio_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Strengthening-Mercks-Life-Science-Portfolio.webp https://thepharmadata.com/cvs-health-and-aetna-award-750000-to-support/ 2025-01-08T10:27:05+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/CVS-Health-and-Aetna-Award-750000-to-Support-Health-Initiatives-in-Illinois_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/CVS-Health-and-Aetna-Award-750000-to-Support-Health-Initiatives-in-Illinois-2_11zon-1024x682.webp https://thepharmadata.com/allergan-aesthetics-launches-coolmonth/ 2025-01-08T10:41:49+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/CoolMonth-Returns-with-Exclusive-Deals-on-CoolSculptingu00ae-Elite-by-Allergan-Aesthetics_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Allergan-Aesthetics-Launches-CoolMonth-Exclusive-Deals-on-CoolSculptingu00ae-Elite.webp https://thepharmadata.com/osteosarcoma-gsks-b7-h3-adc-gsk227-gains-fda/ 2025-01-08T11:03:05+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/GSKu2019s-B7-H3-ADC-GSKu201927-Gains-FDA-Breakthrough-Designation-for-Osteosarcoma_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/GSKu2019s-B7-H3-ADC-GSKu201927-Gains-FDA-Breakthrough-Designation-for-Osteosarcoma-2_11zon-1024x683.webp https://thepharmadata.com/wp-content/uploads/2025/01/Medical-Need-in-Osteosarcoma-1024x489.webp https://thepharmadata.com/alzheimers-disease-unveiling-the-mechanism/ 2025-01-08T11:29:38+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Unveiling-the-Mechanism-Behind-Lecanemabs-Role-in-Slowing-Alzheimers-Disease-Progression.webp https://thepharmadata.com/wp-content/uploads/2025/01/Alzheimers-Disease-Unveiling-the-Mechanism-Behind-Lecanemabs-Role-in-Slowing-Progression-1024x682.webp https://thepharmadata.com/biopharma-a-cautiously-optimistic-outlook/ 2025-01-08T11:47:10+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Opinion-A-Cautiously-Optimistic-Outlook-for-Biopharma-in-2025_11zon-scaled.webp https://thepharmadata.com/wp-content/uploads/2025/01/Therapeutic-Areas-to-Watch_11zon_11zon.webp https://thepharmadata.com/bio-techne-wins-second-claim-of-reverse-eng/ 2025-01-08T12:02:38+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Bio-Techne-Wins-Second-Claim-of-Reverse-Engineering-Against-Miltenyi-Biotec_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Bio-Techne-Prevails-in-Second-Legal-Claim-Against-Miltenyi-Biotec.webp https://thepharmadata.com/malaria-who-approves-test-for-safer-p-vivax/ 2025-01-09T09:27:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WHO-Approves-Test-for-Safer-P.-vivax-Malaria-Treatment_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Malaria-WHO-Approves-Test-for-Safer-P.-vivax-Treatment-1024x683.webp https://thepharmadata.com/announces-breakthrough-g-rex-grant-125000/ 2025-01-09T10:06:31+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/ScaleReady-Announces-G-Rex®-Grant-Awarded-to-Seattle-Childrens-Therapeutics.webp https://thepharmadata.com/wp-content/uploads/2025/01/Childrens-Therapeutics-ScaleReady-Announces-G-Rex®-Grant-Awarded-to-Seattle-Childrens-1.webp https://thepharmadata.com/groundbreaking-glucocorticoid-treatment-neutral/ 2025-01-09T10:30:52+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Neurocrine-Biosciences-Publishes-Study-on-Glucocorticoid-Treatment-in-Congenital-Adrenal-Hyperplasia_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Emerging-Therapies-Non-Glucocorticoid-Mechanisms-for-Managing-CAH_11zon-1024x640.webp https://thepharmadata.com/cardiometabolic-disease-treatments-valo-health/ 2025-01-09T10:56:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Valo-Health-and-Novo-Nordisk-Expand-Collaboration-on-Cardiometabolic-Disease-Treatments_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Cardiometabolic-Disease-Treatments-Valo-Health-and-Novo-Nordisk-Expand-Collaboration_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Cardiometabolic-Disease-Treatment_11zon.webp https://thepharmadata.com/poseida-therapeutics-roche-majority-acquires/ 2025-01-09T11:19:59+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Roche-Acquires-Shares-in-Tender-Offer-for-Poseida-Therapeutics_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Strategic-Rationale-for-the-Acquisition-1-1024x683.webp https://thepharmadata.com/wp-content/uploads/2025/01/Poseidas-Employees-and-Operations-1024x683.webp https://thepharmadata.com/ailux-biologics-ucb-collaborates-with-xtalpi/ 2025-01-10T10:14:12+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Ailux-Biologics-UCB-Collaborates-with-XtalPi-Division-to-Advance-AI-Powered-Biologics-Platform_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Ailux-Biologics-UCB-Collaborates-with-XtalPi-Division-to-Advance-AI-Powered-Biologics-Platform_11zon-1024x685.jpeg https://thepharmadata.com/biologics-license-grifols-submits-fibrinogen/ 2025-01-10T10:49:29+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Grifols-Submits-Biologics-License-Application-to-U.S.-FDA-for-Innovative-Fibrinogen-Solution_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Critical-Medical-Need-1024x536.webp https://thepharmadata.com/wp-content/uploads/2025/01/Fibrinogen-Solution_11zon-1.webp https://thepharmadata.com/promising-formulation-of-new-sarclisa/ 2025-01-10T11:18:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/New-Sarclisa-Subcutaneous-Formulation-Meets-Co-Primary-Endpoints-in-IRAKLIA-Phase-3-Study_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Clinical-Impact_11zon-1024x576.jpeg https://thepharmadata.com/osimertinib-compared-and-promising-survival/ 2025-01-11T11:37:35+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/RYBREVANT®-LAZCLUZE™-Shows-Significant-Survival-Benefit-Over-Osimertinib.webp https://thepharmadata.com/wp-content/uploads/2025/01/Therapy_11zon-1-1024x683.webp https://thepharmadata.com/regenerative-medicine-protein-portfolio/ 2025-01-11T12:14:53+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Bio-Techne-Expands-AI-Engineered-Protein-Portfolio-for-Cell-Therapy-and-Regenerative-Medicine_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Cellular-Therapy_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Regenerative-Medicine-Breakthroug-Bio-Techne-Expands-AI-Engineered-Protein-Portfolio-for-Cell-Therapy_11zon-1024x549.webp https://thepharmadata.com/heart-failure-bayer-files-fda-and-cde/ 2025-01-11T13:03:04+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Bayer-Files-FDA-and-CDE-Applications-for-Finerenones-New-Heart-Failure-Indication_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Heart-Failure-Treatment_11zon-1024x536.webp https://thepharmadata.com/blueprint-medicines-shares-2025-outlook-and/ 2025-01-15T10:22:15+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Blueprint-Medicines-Shares-2025-Outlook-and-Strategic-Plans-for-Sustained-Growth_11zon-1.webp https://thepharmadata.com/wp-content/uploads/2025/01/Blueprint-Medicines-Shares-2025-Outlook-and-Strategic-Plans-for-Sustained-Growth-2_11zon.webp https://thepharmadata.com/ascendis-pharma-shares-unveils-bold-strategic/ 2025-01-13T10:35:28+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Ascendis-Pharma-Shares-Strategic-Update-at-J.P.-Morgan-Healthcare-Conference_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Ascendis-Pharma-Strategic-Vision-and-Growth-Opportunities_11zon-1024x682.webp https://thepharmadata.com/wp-content/uploads/2025/01/TransCon-PTH_11zon-1024x576.webp https://thepharmadata.com/alnylam-strongly-reports-q4-2024-revenues-2025/ 2025-01-13T11:06:45+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Alnylam-Reports-Q4-2024-Revenues-2025-Revenue-Guidance-and-Pipeline-Goals_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Financial-Reports_11zon-1024x682.webp https://thepharmadata.com/pharmaceutical-supply-chain-initiative-proudly/ 2025-01-13T11:31:52+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WuXi-AppTec-Partners-with-Pharmaceutical-Supply-Chain-Initiative_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Pharmaceutical-Supply-Chain-Initiative-Welcomes-WuXi-AppTec-as-Partner_11zon.webp https://thepharmadata.com/pharma-partners-gilead-and-leo-pharma-to-stat6/ 2025-01-13T11:50:24+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Gilead-and-LEO-Pharma-Partner-to-Accelerate-Oral-STAT6-Program-for-Inflammatory-Diseases_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Pharma-Partners-Gilead-and-LEO-Pharma-to-Accelerate-Oral-STAT6-Program-for-Inflammatory-Diseases_11zon-1024x625.webp https://thepharmadata.com/lilly-to-acquire-scorpion-therapeutics-precision/ 2025-01-15T16:24:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Lilly-to-Acquire-Scorpion-Therapeutics-Precision-PI3Kα-Inhibitor-Program-1.webp https://thepharmadata.com/wp-content/uploads/2025/01/Lilly-to-Acquire-Scorpion-Therapeutics-Precision-PI3Kα-Inhibitor-Program-2-1024x537.webp https://thepharmadata.com/lilly-updates-2024-revenue-forecast-announces/ 2025-01-15T16:37:21+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Lilly-Updates-2024-Revenue-Forecast-and-Announces-2025-Guidance_11zon.webp https://thepharmadata.com/wp-content/uploads/2024/11/Baxter-Announces-Third-Quarter-2024-Financial-Results_11zon-1024x682.webp https://thepharmadata.com/abbvie-simcere-partner-antibody-sim0500/ 2025-01-15T17:01:02+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/AbbVie-Simcere-Partner-on-Trispecific-Antibody-for-Multiple-Myeloma_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/AbbVie.webp https://thepharmadata.com/datopotamab-deruxtecan-receives-2025/ 2025-01-15T17:15:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Datopotamab-Deruxtecan-Receives-Priority-Review-for-Advanced-EGFR-NSCLC_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Datopotamab.webp https://thepharmadata.com/sarclisa-secures-1st-approval-in-china/ 2025-01-15T17:19:38+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Sarclisa-Secures-First-Approval-in-China-for-RelapsedRefractory-Multiple-Myeloma_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Approval.webp https://thepharmadata.com/mirevo-japans-neuropsychological-test/ 2025-01-15T17:24:03+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/MIREVO-Japans-First-Neuropsychological-Test-for-Dementia-Treatment-Now-Available_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Neuropsychological.webp https://thepharmadata.com/participants-enrolled-in-askbio-phase/ 2025-01-15T17:28:06+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/First-Participants-Enrolled-in-AskBio-Phase-II-Gene-Therapy-Trial-for-Parkinsons-Disease_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/AskBio.webp https://thepharmadata.com/bayers-pharma-growth-strategy-advances/ 2025-01-15T17:32:35+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Bayers-Pharma-Growth-Strategy-Advances-as-Pipeline-Progresses_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Bayer.jpg https://thepharmadata.com/pheno-therapeutics-receives-clinical-trial/ 2025-01-15T17:37:04+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Pheno-Therapeutics-Receives-Clinical-Trial-Authorization-for-MS-Candidate-PTD802_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Clinical-Trial.webp https://thepharmadata.com/orion-nomination-committees-2025-agm-proposals/ 2025-01-18T10:10:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Orion-Nomination-Committees-2025-AGM-Proposals_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Orion-Nomination-Committees-2025-AGM-Proposals-1024x281.webp https://thepharmadata.com/who-launches-1-5b-health-emergency-appeal/ 2025-01-18T10:14:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WHO-Launches-1.5B-Health-Emergency-Appeal_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/WHO-Launches-1.5B-Health-Emergency-Appeal-1024x329.webp https://thepharmadata.com/incyte-and-syndax-announce-fda-approval-of/ 2025-01-18T10:17:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Incyte-and-Syndax-Announce-FDA-Approval-of-Niktimvou2122-Axatilimab-in-9-mg-and-22-mg-Vials_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Incyte-and-Syndax-Announce-FDA-Approval-of-Niktimvou2122-Axatilimab-in-9-mg-and-22-mg-Vials.webp https://thepharmadata.com/walgreens-resources-for-the-quad-demic-vaccines/ 2025-01-18T12:24:31+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Walgreens-Resources-for-the-Quad-demic-Vaccines-Treatments-and-Support_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Walgreens-Resources-for-the-Quad-demic-Vaccines-Treatments-and-Support.webp https://thepharmadata.com/ucb-highlights-a-decade-of-growth-and-patient/ 2025-01-18T12:36:49+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/UCB-Highlights-a-Decade-of-Growth-and-Patient-Centered-Innovation-Strategy_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/UCB.jpg https://thepharmadata.com/jpm-highlights-wuxi-biologics-ceo-dr-chris-chen/ 2025-01-18T12:41:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/JPM-Highlights-WuXi-Biologics-CEO-Dr.-Chris-Chen-Ready-for-Rapid-Expansion_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/WuXi-Biologics-CEO-Dr.-Chris-Chen-Ready-for-Rapid-Expansion-1024x353.webp https://thepharmadata.com/fda-approves-lillys-omvoh-for-crohns-disease/ 2025-01-18T12:43:25+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/FDA-Approves-Lillys-Omvoh-for-Crohns-Disease-Expanding-Use-in-Inflammatory-Bowel-Disease_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Omvoh-for-Crohns-Disease-Expanding-Use-in-Inflammatory-Bowel-Disease.webp https://thepharmadata.com/biomedical-collaboration-neural-biomarker/ 2025-01-18T12:51:12+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Neuraly-Enigma-Biomedical-USA-Partner-on-PET-Imaging-Biomarker-PMI04_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Biomedical-Collaboration-Neuraly-Enigma-Biomedical-USA-Partner-on-PET-Imaging-Biomarker-PMI04_11zon-1.webp https://thepharmadata.com/medical-device-breakthrough-wuxi-strategically/ 2025-01-18T13:02:43+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WuXi-AppTec-to-Sell-U.S.-Medical-Device-Testing-Operations-to-NAMSA-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Medical-Device-WuXi-AppTec-to-Sell-U.S.-Testing-Operations-to-NAMSA_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Medical-Device-WuXi-AppTec-to-Sell-U.S.-Testing-Operations-to-NAMSA-2_11zon.webp https://thepharmadata.com/ceasefire-in-gaza-offers-hope-amidst-significant/ 2025-01-20T10:52:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Ceasefire-in-Gaza-Offers-Hope-Amidst-Significant-Challenges-to-Rebuild-the-Health-System_11zon-1.webp https://thepharmadata.com/wp-content/uploads/2025/01/Ceasefire-in-Gaza-Offers-Hope-Amidst-Significant-Challenges-to-Rebuild-the-Health-System.webp https://thepharmadata.com/experimental-breast-cancer-drug-shows-potential/ 2025-01-20T10:59:24+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Experimental-Breast-Cancer-Drug-Shows-Potential-to-Treat-Certain-Blood-Cancers_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Experimental-Breast-Cancer-Drug-Shows-Potential-to-Treat-Certain-Blood-Cancers-1024x682.webp https://thepharmadata.com/global-survey-on-breakthrough-tech-attitudes/ 2025-01-21T14:49:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Leaps-by-Bayer-Launches-Global-Survey-on-Breakthrough-Tech-Attitudes_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/leaps-by-bayer-launches-global-survey-on-breakthrough-tech-attitudes-678f64ae49dc5.webp https://thepharmadata.com/gaza-ceasefire-brings-hope-but-health-system/ 2025-01-21T15:10:05+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Gaza-Ceasefire-Brings-Hope-but-Health-System-Challenges-Remain-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Gaza-Ceasefire-Brings-Hope-but-Health-System-Challenges-Remain.avif https://thepharmadata.com/poxel-to-gain-increased-royalties-from-sumitomo/ 2025-01-21T16:06:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Poxel-to-Gain-Increased-Royalties-from-Sumitomo-Pharma-for-TWYMEEGu00ae-Sales-in-Japan_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Poxel-to-Gain-Increased-Royalties-from-Sumitomo-Pharma-for-TWYMEEG-Sales-in-Japan-1024x698.webp https://thepharmadata.com/aseptic-filling-machine-market-forecast-to-2035/ 2025-01-21T15:57:38+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Aseptic-Filling-Machine-Market-Forecast-to-2035-Key-Players-Profiled_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Aseptic-Filling-Machine-Market-Forecast-to-2035-Key-Players-Profiled-1024x682.webp https://thepharmadata.com/poxel-secures-patent-in-china-for-imeglimin-use/ 2025-01-21T16:03:51+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Poxel-Secures-Patent-in-China-for-Imeglimin-Use-in-Type-2-Diabetic-Patients-with-Renal-Impairment_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Poxel-Secures-Patent-in-China-for-Imeglimin-Use-in-Type-2-Diabetic-Patients-with-Renal-Impairment-1024x682.webp https://thepharmadata.com/who-responds-to-u-s-announcement-of-withdrawal/ 2025-01-22T10:12:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/WHO-Responds-to-U.S.-Announcement-of-Withdrawal-Intent_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/WHO-Responds-to-U.S.-Announcement-of-Withdrawal-Intent-2_11zon-1024x682.webp https://thepharmadata.com/brainchild-bio-receives-prestigious-g-rex-grant/ 2025-01-22T10:38:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/ScaleReady-Awards-Prestigious-G-Rex®-Grant-to-BrainChild-Bio.webp https://thepharmadata.com/wp-content/uploads/2025/01/ScaleReady-Awards-Prestigious-G-Rex®-Grant-to-BrainChild-Bio-2-1024x400.webp https://thepharmadata.com/phase-2-trial-cytokinetics-launches-amber-hfpef/ 2025-01-22T10:47:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Cytokinetics-Launches-AMBER-HFpEF-Phase-2-Trial-of-CK-586-in-Symptomatic-HFpEF-Patients_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Cytokinetics-Launches-AMBER-HFpEF-Phase-2-Trial-of-CK-586-in-Symptomatic-HFpEF-Patients-2_11zon.webp https://thepharmadata.com/sarclisa-approved-in-eu-for-treating-transplant/ 2025-01-24T16:08:26+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Sarclisa-Approved-in-EU-for-Treating-Transplant-Ineligible-Newly-Diagnosed-Multiple-Myeloma_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Sarclisa-Approved-in-EU-for-Treating-Transplant-Ineligible-Newly-Diagnosed-Multiple-Myeloma-1024x642.webp https://thepharmadata.com/roche-gets-fda-clearance-for-clia-waived-sti-p/ 2025-01-24T16:12:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Roche-Gets-FDA-Clearance-for-CLIA-Waived-STI-Point-of-Care-Tests_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Roche-Gets-FDA-Clearance-for-CLIA-Waived-STI-Point-of-Care-Tests.webp https://thepharmadata.com/salubris-biotherapeutics-reports-positive-interi/ 2025-01-27T16:04:25+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Salubris-Biotherapeutics-Reports-Positive-Interim-Data-from-Phase-2-Heart-Failure-Trial-of-JK07_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Salubris-Biotherapeutics-Reports-Positive-Interim-Data-from-Phase-2-Heart-Failure-Trial-of-JK07-edited.webp https://thepharmadata.com/arcus-biosciences-names-richard-markus-m-d-ph/ 2025-01-27T16:19:08+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Arcus-Biosciences-Names-Richard-Markus-M.D.-Ph.D.-as-Chief-Medical-Officer_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Arcus-Biosciences-Names-Richard-Markus-M.D.-Ph.D.-as-Chief-Medical-Officer-1024x357.webp